Digital breast tomosynthesis (DBT) is a 3D breast imaging technique built on full field digital mammography technology. DBT systems creates multiple projection images of the breasts obtained from different angles of the rotating X-Ray tube at a low radiation dose through the compressed breast. Images are reconstructed into multiple slices of 1mm thickness and viewed on a dedicated monitor approved for tomosynthesis. This minimises the impact of tissue superimposition resulting in better visualisation of the internal structures. Conventionally, breast screening was performed step by step, starting with full-field digital mammography (FFDM or 2D mammography) followed by digital breast tomosynthesis (3D mammography) or breast Magnetic Resonance Imaging (MRI). FFDM is considered the gold standard in breast cancer screening. However, with the advent of DBT technology, it is slowly being replaced. DBT is frequently used as an adjunct technique with FFDM. Research and studies are being undertaken to consider DBT as a primary screening tool, particularly in patients with dense breasts. 3D mammography has proven to be better than 2D mammography in multiple clinical trials, which has led to an increase in its adoption. Combination of 2D and 3D mammography has become the new standard of care since 3D mammography compliments conventional 2D mammography.
Market Value and Forecast
The global digital breast tomosynthesis equipment market was valued at US$ 886.6 Mn in 2015, and is projected to expand at a CAGR of 13.9% over forecast period 2016–2026. Increasing adoption of 3D mammography due to superior features over 2D mammography and favourable regulatory backing are factors fuelling market growth across the globe. The digital breast tomosynthesis equipment market would be driven by both new equipment purchases and upgradation of existing digital mammography machines.
Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1241
Drivers and Trends
Risk of developing cancer is directly proportional to age. Increasing life expectancy in developing countries and adoption of unhealthy lifestyles due to rampant urbanisation and westernisation are driving incidence rate of cancer among the population in these countries. Although, incidence of breast cancer has reduced in developed countries due to several preventive measures implemented by various government and non-governmental organisations, incidence rate of breast cancer is increasing at a steady rate. These factors are expected to increase the prevalence and diagnosis of breast cancer over the forecast period. DBT machines, with their superior sensitivity and specificity in comparison to conventional 2D mammography, reduces false positive recalls and offers better cancer detection especially, invasive cancer detection. DBT reduces the need to revisit for additional breast imaging by around 15%, thereby reducing costs, psychological distress, time and discomfort caused by a false negative recall. DBT equipment manufacturers are providing software and hardware upgrades for existing full film digital mammography systems which addresses the financial impact of buying new equipment.
Analysis by End User
By end user, the global digital breast tomosynthesis equipment market is segmented into hospitals and diagnostic centres. In terms of revenue, hospitals segment is expected to expand at a CAGR of 14.9% during the forecast period.
Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-1241
Analysis by Region
On the basis of geography, the digital breast tomosynthesis equipment market has been segmented into seven major regions namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA). In terms of value, North America market has been estimated to dominate the global digital breast tomosynthesis equipment market in 2016 and is expected to witness the highest CAGR of 2.4% over the forecast period. The digital breast tomosynthesis equipment markets in MEA, North America and Western Europe are estimated to register higher CAGRs as compared to other regional markets. In terms of value, North America market is expected to expand at a CAGR of 14.5% over the forecast period. New equipment sales in the North America market is expected to register a CAGR of 16.0% during the forecast period and is expected to be valued at US$ 2.1 Bn by 2026 end.
Some of the key players identified in the global digital breast tomosynthesis equipment market report include Hologic Inc., Siemens Healthineers, Fujifilm Corporation, GE Healthcare, Internazionale Medico Scientifica S.r.l. and Planmed OY The report offers valuable insights into company-specific strategies, market consolidation initiatives and analyses of the various market players’ specific strengths, weaknesses, opportunities and threats related to the global digital breast tomosynthesis equipment market.